What question did this study set out to answer?

This study aims to evaluate the efficacy of 177Lu-PSMA in combination with immunotherapy and DDR inhibitors in a prostate cancer model.

Theranostic Evaluation of PSMA Therapy and Combination Treatments in Prostate Cancer Models

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the efficacy of 177Lu-PSMA in combination with immunotherapy and DDR inhibitors in a prostate cancer model.
Conducted in vivo study using male immunodeficient mice with LNCaP tumours.
Mice underwent baseline 18F-PSMA PET/CT imaging to confirm tumour characteristics.
Randomised into six treatment cohorts including monotherapy and combinations.
Monitored responses using longitudinal imaging and measurements of tumour volume and weight.
Performed blood analyses post-treatment for pharmacokinetics and toxicity evaluations.
18F-PSMA-PET imaging correlated with therapeutic efficacy of 177Lu-PSMA.
177Lu monotherapy showed significant anti-tumour effects with reduced toxicity.
Combination with anti-PD-1 increased treatment effectiveness through radiosensitisation.
Triple combination therapy led to maximum tumour suppression with manageable side effects.
Ex vivo biomarker analyses provided insights into treatment mechanisms and predictive correlates.

No takes yet. Share an insight, caveat, or question.

In vivo study evaluates 177Lu-PSMA therapy and combination treatments in an LNCaP xenograft model, suggesting enhancements in therapeutic efficacy.

Maynard et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

In vivo study evaluates 177Lu-PSMA therapy and combination treatments in an LNCaP xenograft model, suggesting enhancements in therapeutic efficacy.